Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Pfizer Inc | 107 |
| 2 | Mass General Brigham Inc | 52 |
| 3 | National Research Council of Science and Technology | 46 |
| 4 | The University of Texas System | 46 |
| 5 | Massachusetts Institute of Technology | 39 |
| 6 | Alnylam Pharmaceuticals Inc | 30 |
| 7 | Novartis AG | 28 |
| 8 | Aquestive Therapeutics Inc | 25 |
| 9 | Harvard University | 25 |
| 10 | Gilead Sciences Inc | 23 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 1,019 |
| 2 | A61P | Therapeutic activity (drug indications) | 1,001 |
| 3 | Y02A | Climate change adaptation | 341 |
| 4 | C12N | Microorganisms, enzymes | 333 |
| 5 | C07D | Heterocyclic compounds | 315 |
| 6 | C07K | Peptides | 186 |
| 7 | C07H | Sugars and derivatives | 103 |
| 8 | C07C | Acyclic and carbocyclic compounds | 78 |
| 9 | A61M | Devices for introducing media into the body | 49 |
| 10 | B82Y | Nanotechnology | 42 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee |
|---|---|---|
| Analogs of arildone | 1994 | Merck and Co Inc |
| Analogs of arildone | 1992 | Merck and Co Inc |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Francis Pancic | Sterling Research Group (United States) | 4 |
| 2 | Jerome Edelson | Sterling Research Group (United States) | 3 |
| 3 | Lawrence A. Caliguiri | Albany Medical Center Hospital | 2 |
| 4 | John A. Bosso | University of Utah | 2 |
| 5 | Ethel S. Zalay | 2 |
| 6 | James J. McSharry | Albany Medical Center Hospital | 2 |
| 7 | A.S. Tyms | St. Mary’s Hospital | 2 |
| 8 | Albert Boeyé | Vrije Universiteit Brussel | 2 |
| 9 | R. Vrijsen | Vrije Universiteit Brussel | 2 |
| 10 | David P. Benziger | Sterling Research Group (United States) | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Effect of arildone on modifications of poliovirus in vitro | 1980 | 66 | Virus-based gene therapy research |
| Eclipse products of poliovirus after cold-synchronized infection of HeLa cells | 1989 | 64 | Viral gastroenteritis research and epidemiology |
| Effect of dichloroflavan (BW683C) on the stability and uncoating of rhinovirus type 1B | 1984 | 36 | Respiratory viral infections research |
| Antiviral activity of arildone on deoxyribonucleic acid and ribonucleic acid viruses | 1980 | 33 | HIV Research and Treatment |
| Prevention of human poliovirus-induced paralysis and death in mice by the novel antiviral agent arildone | 1982 | 31 | RNA Research and Splicing |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Arildone?
Which organizations hold the most patents related to Arildone?
What was the trend in Arildone patent filings over the past decade?
What research topics are most associated with Arildone in published literature?
Which CPC subclasses dominate the patent landscape for Arildone-related inventions?